SCM
NVLN

Stonepine Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Stonepine Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,909,207
Closed -$2.76M – 33
2019
Q4 		$2.76M Buy
3,909,207
+205,787
+6% +$146K 1.92% 15
2019
Q3 		$2.69M Buy
3,703,420
+3,212,324
+654% +$2.33M 2.61% 15
2019
Q2 		$383K Buy
+491,096
New +$546K 0.26% 24
2019
Q1 		– Sell
-531,662
Closed -$447K – 36
2018
Q4 		$447K Sell
531,662
-1,197,225
-69% -$1.35M 0.39% 21
2018
Q3 		$5.12M Sell
1,728,887
-64,024
-4% -$227K 2.99% 12
2018
Q2 		$6.6M Sell
1,792,911
-67,089
-4% -$269K 4.01% 10
2018
Q1 		$6.51M Buy
1,860,000
+165,283
+10% +$701K 3.49% 10
2017
Q4 		$5.29M Sell
1,694,717
-131,647
-7% -$633K 3.17% 12
2017
Q3 		$12.8M Sell
1,826,364
-26,031
-1% -$209K 7.57% 5
2017
Q2 		$17.1M Buy
1,852,395
+291,908
+19% +$2.81M 9.23% 3
2017
Q1 		$16.8M Buy
1,560,487
+36,453
+2% +$373K 9.44% 3
2016
Q4 		$12.8M Buy
+1,524,034
New +$13.5M 7.64% 6

Stonepine Capital Management's NVLN Position: Q1 2020 in Review

Stonepine Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2020, closing a stake of 3,909,207 shares — an estimated $2.76M sold.

Stonepine Capital Management first reported a position in NVLN in Q4 2016 and held it in 12 quarters. The position peaked at $17.1M in Q2 2017. 1 fund tracked by Wall St. Rank holds NVLN as of Q1 2020.

  • Stonepine Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2020 after selling out during the quarter.
  • Stonepine Capital Management sold 3,909,207 Novelion Therapeutics Inc. Common Shares shares in Q1 2020, an estimated $2.76M.
  • Stonepine Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 12 quarters.
  • Stonepine Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $17.1M in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2020.

Based on Stonepine Capital Management's 13F filing for Q1 2020, filed 14 May 2020.